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METHODS: Data were collected from men enrolled in the multicenter Canary PASS with Gleason 3+4, < 34% of biopsy cores positive, and no 5ARI use. PSA was collected every 3 months, and biopsies were performed at 6-12 months, 24 months, and then every 2 years from diagnosis. PSA velocity (PSAV) was determined by calculating a best linear unbiased predictor at each time point based on a linear mixed effect model (LMEM) that accounted for past and present serial logged PSA levels. The association of diagnostic PSA and/or PSAV with time to reclassification (increase in Gleason grade and/or increase to 34% of cores positive) was evaluated using Cox proportional hazards models. Models were adjusted for age, prostate size, biopsy parameters, and used serial PSA collected every 3 or every 6 months, where applicable.
RESULTS: 908 men met study criteria, of whom 288 (32%) had a reclassification event within 5 years. Median follow up was 2.9 years. After adjusting for age, prostate size, biopsy parameters, and diagnostic PSA, PSAV was a significant predictor of reclassification (HR for each 10% increase in PSAV ¼ 1.7 (95% CI 1.3-2.1, p < .0001). The PSAV model had slightly improved accuracy over diagnostic PSA at 3 year prediction: AUC for diagnostic PSA model was 0.79 (95% CI 0.73-0.83) and for PSAV model was 0.80 (95% CI 0.75-0.84). Model performance was essentially identical using calculations based on q6 month rather than q3 month PSAs.
CONCLUSIONS: PSA velocity calculated using LMEM significantly predicts biopsy reclassification. Models that use repeat PSA measurements outperform a model with diagnostic PSA only. Model performance is similar using PSA assessed every 3 or 6 months. These results inform how PSA may be incorporated into active surveillance protocols and risk calculators. (PASS, NCT00756665, clinicaltrials.gov ). An easy to use on line predictive tool of progression in FU biopsy (Bx) hasbeen proposed by the PASS group, the PASSRisk Calculator (PASSRC). We perform an external validation of the PASSRC in our series, specially focused on clinical utility of PASSRC by selecting cutoff points of probability for clinical decision counselling.
METHODS: After matching for validation purposes, we select 498 patients with a minimum of one follow-up Bx; no other exclusion criteria were considered nor bias has been detected. PASSRC external validation is done by means of calibration curve and area under de ROC curve (AUC), identifying cutoffs of clinical utility by probability density functions (PDF) and clinical utility curves (CUC).
RESULTS: We find significant differences in age, PSA and clinical stage between our validation cohort and the PASSRC generation cohort (p<.0001), with a progression rate of 10-22% on the successive follow-up Bx. No cancer was found in 44% of the first followup Bx. The calibration curve shows underestimation of observed progression. The AUC is 0.65 (C.I.95%: 0.60-0.71). PDF and CUC do not suggest a specific cutoff point for clinical use, because of the overlap of the distributions of probabilities between progressing and non-progressing patients CONCLUSIONS: In the first external validation of the PASSRC we have obtained a moderate discrimination ability. Unfortunately, we cannot recommend cutoffpoints of clinical use from our study. Specific risk calculators from different cohort features, different prognosis models or the inclusion of new biomarkers and/or morphofunctional parameters from mpMRI should be stressed as potential predictors for progression within AS strategies METHODS: We conducted a retrospective analysis of men undergoing RP from 1995-2015 and identified 2 groups; 122 men in AS who underwent RP following GR (7(3+4) or greater, grade group 2 and above) and 4433 men who underwent immediate RP (IRP) following a diagnosis of grade group 2 and above. bRFS was assessed using Kaplan Meir and multivariate Cox regression analyses.
RESULTS: Of 122 men in AS, 13 (10.7%) had biochemical recurrence (BCR) as compared to 777 of 4,433 (17.5%) men that underwent IRP (p ¼0.007). As compared to the IRP group, men on AS were significantly older (p <0.001), had a higher proportion of low volume cancers (p <0.001), a lower PSA density (p ¼0.001), and a lower rate of GS upgrade at surgery (p <0.001). bRFS was higher for men in the AS cohort compared to IRP group (p ¼ 0.046, e558 THE JOURNAL OF UROLOGY â Vol. 197, No. 4S, Supplement, Saturday, May 13, 2017 
